Who are batch 3 of Ad5-nCoV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ad26.COV2.S vaccine, COVAX only (1st and 2nd dose), protein subunit: Novavax COVID-19 vaccine, BioNTech - Pfizer COVID-19 vaccine, AntiCov-220, Novavax recombinant protein vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/batch-3-of-ad5-ncov.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

batch 3 of Ad5-nCoV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

batch 3 of Ad5-nCoV (batch 3 of Ad5-nCoV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: viral vector vaccine. Area: Immunology / Infectious Disease.

marketed viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

batch 3 of Ad5-nCoV (batch 3 of Ad5-nCoV) — Jiangsu Province Centers for Disease Control and Prevention. Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
batch 3 of Ad5-nCoV TARGET	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
BioNTech - Pfizer COVID-19 vaccine	BioNTech - Pfizer COVID-19 vaccine	University of Birmingham	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (viral vector vaccine class)

Jiangsu Province Centers for Disease Control and Prevention · 3 drugs in this class
University Medical Center Groningen · 1 drug in this class
Vinbiocare Biotechnology Joint Stock Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). batch 3 of Ad5-nCoV — Competitive Intelligence Brief. https://druglandscape.com/ci/batch-3-of-ad5-ncov. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab